KRAS and cancer: In one paper by Solanki and colleagues, NSCLCs with an epithelial gene signature tended to upregulate ERBB2/3 signaling in response to KRAS repression, while cancers with a mesenchymal signature relied more on FGFR1 and AXL signaling [87].